1. Barriers to Rare Disease Therapy: Too Expensive and Too Slow

For patients with rare genetic disorders, CRISPR gene editing is often the only hope, yet the practical barriers remain formidable. Designing and manufacturing a patient‑specific guide RNA can cost hundreds of millions of Korean won and take several months. Consequently, many patients are unable to access therapies even when they are developed, leading to repeated tragic outcomes.

2. Integration of Modular Automation and 3D Printing: A Paradigm Shift in Production

To address this challenge, the research team implemented an automated modular production line combined with 3D‑printing technology. Analogous to fabricating custom components in a factory, a robotic system automatically assembles guide RNAs and Cas9 protein tailored to each patient’s genetic variant. As a result, a process that previously required weeks was compressed to a few days, enabling the simultaneous manufacture of thousands of personalized therapeutics.

3. Demonstrating 70% Cost Reduction and Clinical Success

In an early‑phase clinical trial involving 12 patients, the technology’s value became evident. The personalized therapeutics exhibited efficacy exceeding expectations, and production costs were reduced by 70% relative to conventional methods. This economic advantage provided a decisive impetus for traditionally cautious regulators and insurers to consider broader adoption of gene therapies.

4. Future Significance and Outlook

If this personalized platform becomes widespread within the next five years, thousands of patients with rare diseases stand to benefit. Beyond mere cost savings, this represents a historic shift from a “mass‑production” model to an “on‑demand, patient‑specific” paradigm for rare disease therapy. As the technology expands to address a broader spectrum of genetically driven conditions, a true era of precision medicine—where every individual receives treatment tailored to their genome—will be realized.